Turn Therapeutics Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Bradley Burnam (CEO) and Zuraiz Chaudhary (Interim CFO) signed standard Sarbanes-Oxley certifications on August 12, 2026 for the June 30, 2026 quarterly report. Both officers attest that disclosure controls, internal controls over financial reporting are effective, no material weaknesses or fraud were identified, and financial statements fairly present the company's condition. No specific operational, financial, or strategic developments are disclosed in these certification exhibits.
Why this rating
Routine SOX certifications with no disclosed control deficiencies or fraud. No concrete business impact; standard periodic filing requirement.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.